Palo Alto Investors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Palo Alto Investors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-32,320	Closed	-$14.7M	–	50
2025 Q3	$14.7M	Sell	32,320 -43,215	-57%	-$17.6M	2.73%	13
2025 Q2	$24.6M	Sell	75,535 -7,953	-10%	-$2.2M	5.24%	7
2025 Q1	$22.5M	Sell	83,488 -57,193	-41%	-$14.7M	4.29%	7
2024 Q4	$33.1M	Hold	140,681	–	–	5.13%	6
2024 Q3	$38.7M	Buy	+140,681	New	+$36.6M	5.03%	8
2024 Q2	–	Sell	-182,766	Closed	-$27.3M	–	40
2024 Q1	$27.3M	Buy	182,766 +28,329	+18%	+$4.73M	3.08%	10
2023 Q4	$29.6M	Buy	+154,437	New	+$26.3M	2.66%	10

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Palo Alto Investors's ALNY Position: Q4 2025 in Review

Palo Alto Investors sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 32,320 shares — an estimated $14.7M sold.

Palo Alto Investors first reported a position in ALNY in Q4 2023 and held it in 7 quarters. The position peaked at $38.7M in Q3 2024. 851 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

Palo Alto Investors reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Palo Alto Investors sold 32,320 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $14.7M.
Palo Alto Investors first reported a position in Alnylam Pharmaceuticals in Q4 2023 and held it in 7 quarters.
Palo Alto Investors's Alnylam Pharmaceuticals position peaked at $38.7M in Q3 2024.
851 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on Palo Alto Investors's 13F filing for Q4 2025, filed 17 Feb 2026.